Cabozantinib clinical trial recruitment information and conditions for participation

Cabozantinib is a multi-target tyrosine kinase inhibitor mainly used to treat various solid tumors such as renal cancer, hepatocellular carcinoma and medullary thyroid cancer. With its widespread promotion in clinical applications, clinical trials of cabozantinib are also being carried out around the world, aiming to explore its efficacy and safety in different tumor types and treatment stages.

In terms of clinical trial recruitment, cabozantinib research subjects usually include patients who have failed standard treatments or have no standard treatment options. For example, a clinical trial numberedNCT02302833 was designed to evaluate the efficacy of cabozantinib in the treatment of patients with pheochromocytoma and paraganglioma. Inclusion criteria for the trial included histologically confirmed pheochromocytoma or paraganglioma, locally advanced or metastatic disease with unresectable disease, disease progression within the past 12 months, an ECOG performance status of 0 to 2, a life expectancy of at least 3 months, and meeting certain hematological and biochemical parameters.

In addition, another clinical trial numberedNCT03611595 evaluates the efficacy of cabozantinib combined with 13-cis retinoic acid in the treatment of patients with solid tumors. Inclusion criteria for the trial included: histologically confirmed solid tumors, disease progression or recurrence after standard treatment or no standard treatment options, Karnofsky or Lansky performance score ≥40, and recovery from acute toxicities of prior therapy before treatment.

It should be noted that clinical trials of cabozantinib usually have strict requirements on patients’ liver function. For example, in one study of hepatocellular carcinoma, only patients with Child-Pugh A liver function were recruited. Cabozantinib should be used with caution in patients with hepatic impairment and may in some cases be excluded from the trial.

Reference:https://en.wikipedia.org/wiki/Cabozantinib